Shameka McKnight
Nurse Practitioner · Baltimore, MDNPI 1467140483
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,649, more than ten times the $21 reported in 2023. Among nurse practitioner clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$562
- AstraZeneca$447
- GSK$253
- Lilly USA, LLC$204
- Teva Pharmaceuticals USA, Inc.$169
- Amgen$158
- plus $1K from 17 others
What the payments were for
- Food & beverage$2,85899%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $562 |
| AstraZeneca | 13 | $447 |
| GSK | 7 | $253 |
| Lilly USA, LLC | 10 | $204 |
| Teva Pharmaceuticals USA, Inc. | 8 | $169 |
| Amgen | 3 | $158 |
| AbbVie | 8 | $156 |
| Pfizer | 6 | $123 |
| Exact Sciences | 5 | $102 |
| Boehringer Ingelheim | 4 | $99 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $86 |
| Phathom Pharmaceuticals, Inc. | 5 | $86 |
| Astellas Pharma US Inc | 4 | $80 |
| Neurocrine Biosciences, Inc. | 3 | $75 |
| Viiv Healthcare Company | 2 | $51 |
| Dexcom, Inc. | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Gilead | 1 | $34 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,877 in reported general payments places this provider in the 90th percentile of 1,562 nurse practitioner providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $763 |
| Gabapentin | 28 | $341 |
| Fluticasone Propionate | 23 | $175 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 30 | $147 |
| Azithromycin | 33 | $146 |
| Atorvastatin Calcium | 15 | $130 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $99 |
| Montelukast Sodium | 16 | $88 |
| Amlodipine Besylate | 20 | $71 |
| Ibuprofen | 13 | $59 |
| Alprazolam | 12 | $43 |
| Famotidine | 13 | $42 |
| Furosemide | 13 | $39 |
| Prednisone | 13 | $34 |
| Lisinopril | 16 | $32 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Baltimore
- Sherilyn BrinkleyBaltimore$100K
- Michelle TurnerBaltimore$94K
- Zeev NemirovskyBaltimore$19K
- Stephanie HorrocksBaltimore$12K
- Sandra WoodringBaltimore$12K
- Inna BardoffBaltimore$11K
- Linda RyanBaltimore$10K
- Laura HostovichBaltimore$8K
- Denese GaughanBaltimore$7K
- Arita McCoyBaltimore$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.